LPLuca Petricca

Luca Petricca

*This is an algorithmically generated author record based on publicly available information.

Luca Petricca has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of clinical phenotypes and disease trajectories in SLE using AI through a natural language processing framework

    by Silvia Laura Bosello, Augusta Ortolan, Lucia Lanzo, Livia Lilli, Laura Antenucci, Pier Giacomo Cerasuolo, Silvia Piunno, Luca Petricca, Maria Rita Gigante, Viviana Antonella Pacucci, et al.

    Objectives: Electronic health records (EHRs) contain a wealth of unstructured patient data that can be leveraged using artificial intelligence (AI). This study aimed to develop a natural language processing (NLP) pipeline to identify clinical phenotypes and disease trajectories in patients with systemic lupus erythematosus (SLE) from EHRs. Methods: EHR data from SLE patients were included. A standardized stepwise framework combining AI and human intelligence (HI) was designed. Ontology-based definitions were developed for clinical domains, flares and disease complexity phenotypes (low, medium, high) at the first contact, and corresponding data were extracted using an NLP-based pipeline. Results: Out of 1,000 extraxcted patients, inclusion criteria were met by 262 who had ≥1 hospitalization, ≥1outpatient visit, and a follow-up ≥1.5 years. Among these, 88% were female, median age was 43 years, median follow-up 6 years. At first contact, the most frequently involved clinical domains were hematological (64%), articular (47%), cutaneous (59%) and renal (58%). At first contact, 43% of patients presented with a high-complexity phenotype, 35% medium, 22% low complexity: the first group experienced more flares over time (5 vs 3 and 3, P < 0.001). Patients with a low and medium-complexity phenotype showed a higher increase in new clinical domains and in the use of conventional immunosuppressants, biologics and glucocorticoids during follow-up. Conclusion: This novel framework, based on real-world data, enables longitudinal phenotype characterization of SLE patients. It demonstrates promise as a feasible tool to study the heterogeneity of SLE and its progression over time, offering insights into potential applications in clinical research and patient management.


  • Open Access

    The ontogeny of myeloid-stromal synovial tissue niches in rheumatoid arthritis

    by Aziza Elmesmari, Domenico Somma, Lucy MacDonald, Jack Frew, Zuzanna Kuczynska, Clara Di Mario, Lavinia Agra Coletto, Shravani Baruah, Denise Campobasso, Theodoros Simakou, et al.

    Recent single-cell multi-omic and spatial analyses of synovial biopsies have transformed our understanding of myeloid cell–driven mechanisms underlying human joint pathology and tissue homeostasis in Rheumatoid arthritis (RA). However, the developmental trajectories of synovial tissue macrophage (STM) subsets in humans remain poorly understood, due in part to the lack of models that faithfully replicate synovial tissue niches. This hinders the exploration of the therapeutic potential of targeting specific synovial myeloid cell clusters. Using multi-omics analyses of synovial tissue from an allogeneic bone marrow transplant recipient, we show that joint-specific tissue-resident STM subsets, including both health- and disease-associated clusters, can derive from peripheral blood monocytes. Analysis of embryonic synovial joints revealed that macrophage localization and maturation in the joints are preceded by local stromal niche specialisation, indicating that synovial fibroblasts (FLS) provide tissue-specific instructive cues to STM precursors. To elucidate human STM developmental trajectories, we established a SNP-based fate-tracking human synovial organoid system by embedding distinct blood-derived myeloid precursors, together with FLS clusters from RA synovial biopsies and endothelial cells, into 3D structures. These organoids reproduced key synovial tissue features, including lining and sublining architecture and stromal–myeloid cell cluster composition. Importantly, they supported differentiation of all resident STM subsets: homeostatic lining TREM2 pos macrophages, their pathogenic TREM2 low SPP1 pos counterparts that characterize the RA hyperplastic lining, and both homeostatic and RA-associated perivascular LYVE1 pos STM clusters, all traced to monocytic precursors. In summary, we show that development of STM subsets is driven by fibroblast-conditioned spatial niches. We have established a novel, tractable ex vivo platform to dissect the niche-specific cues driving homeostatic versus pathogenic phenotypic clusters. One Sentence Summary: Human tissue-resident STMs develop from monocytes under the guidance of cues from FLS within discrete spatial locations.


  • Open Access

    Distinct tissue-niche localization and function of synovial tissue myeloid DC subsets in health, and in active and remission Rheumatoid Arthritis

    by Lucy MacDonald, Aziza Elmesmari, Domenico Somma, Jack Frew, Clara Di Mario, Roopa Madhu, Audrey Paoletti, Theodoros Simakou, Olympia M. Hardy, Barbara Tolusso, et al.

    Summary: Current rheumatoid arthritis (RA) treatments do not restore immune tolerance. Investigating dendritic cell (DC) populations in human synovial tissue (ST) may reveal pathways to re-instate tolerance in RA. With single-cell and spatial-transcriptomics of synovial tissue biopsies, validated by micro co-culture systems, we identified condition and niche-specific myeloid DC clusters with distinct differentiation trajectories and functions. Healthy synovium contains a unique tolerogenic AXL pos DC2 cluster in the superficial sublining layer. In active RA, a macrophage-rich lining-layer niche becomes populated with inflammatory DC3 clusters that specifically activate memory CCL5 pos TEM and CCL5 pos CXCL13 pos TPH, promoting synovitis. In the sublining lymphoid niche, CCR7 pos DC2 mReg specifically interact with naïve-T-cells, potentially driving the local expansion of new effector T-cells. Sustained remission sees the resolution of these niches but lacks the recovery of tolerogenic AXL pos DC2, indicating latent potential for disease flare. A human RA disease-flare model showed that the activation of blood predecessor of ST-DC3 clusters precedes the onset of inflammation in joints. Therapeutic strategies targeting pathogenic ST-DC3 clusters, or reinstating tolerogenic AXL pos DC2, may restore immune homeostasis in RA. In brief: Deconstruction of human RA synovium, using single-cell spatial transcriptomics and micro-culture systems, reveals distinct neighbourhoods within the synovial architecture across health, and RA patients with active disease or sustained remission. Discrete niches are identified that contain distinct myeloid DC clusters that differ in frequency, differentiation trajectories, and effector functions. Highlights: Human RA synovium exhibits condition and niche specific myeloid DC clusters that vary in their tissue differentiation trajectories and functions. ST-CD14 pos DC3 (iDC3) support inflammatory CCL5 pos TEM and CCL5 pos TPH cell activation in the hyperplastic lining layer. ST-CCR7 pos DC2 (mReg), driven by MIR155, interact with naïve-T-cells in sublining lymphoid niches. A specific inflammatory signature of blood predecessors of ST-DC3s predict flare in RA. Graphical

  • Open Access

    POS1353 SEMIQUANTITATIVE ASSESSMENT OF KNEE OSTEOARTHRITIS-RELATED SYNOVITIS COMPARED TO CHRONIC INFLAMMATORY ARTHRITIDES: RELATION TO AGE AND IMPACT ON BONE/STRUCTURAL DAMAGE

    by P. Rubortone, F. Leone, L. Petricca, S. Perniola, D. Bruno, M. R. Gigante, C. Di Mario, B. Tolusso, G. Peluso, E. Gremese, et al.

    Background Knee Osteoarthritis (KOA) is one of the most frequent causes of pain and disability, representing a relevant clinical burden. Although it was largely considered a mostly mechanical-based pathology, low-grade synovial inflammation was found to contribute to radiographic progression and pain chronicity [1]. Objectives To evaluate the histological characteristics of synovial membrane inflammation in KOA patients compared to chronic inflammatory diseases as Rheumatoid (RA) and Psoriatic Arthritis (PsA) across disease phases. Methods 170 patients with KOA, 240 patients with RA, 92 patients with PsA naive to pharmacological treatments and 200 patients with RA in sustained clinical and ultrasound remission (RA-r) underwent ultrasound-guided synovial biopsy of the knee and conventional X-rays. None of enrolled KOA patient had evidence of inflammatory condition (including chronic inflammatory diseases and crystal related arthritis). Synovial membrane samples were processed for histology (hematoxylin-eosin staining) for the semiquantitative assessment of synovitis degree (Krenn synovitis score [2] - KSS). Moreover, this analysis was implemented with the semiqualitative assessment of presence/absence of synovial lymphocytes, plasmacells, myxoid degeneration and inflammatory perivascular aggregates. X-rays were scored for Kellgren-Lawrence score [3] (KLs) assessment. Results RA and PsA patients naive to pharmacological treatment showed higher degree of synovial inflammation than patients with KOA as well as more likely presence of lymphocytes and plasmacells aggregates. Considering the whole KOA population, total KSS directly correlated with age (R²=0.041; p=0.008), thickness of synovial membrane (R²=0.115; pConclusion KOA-related synovitis represents an unmet clinical need due to still uncovered pathogenetic mechanisms. The severity of KOA-related synovitis impacts on bone structural damage and is related to age, supporting the role of inflammageing in KOA pathogenesis. References [1]Sanchez-Lopez, E., Coras, R., Torres, A., Lane, N. E. & Guma, M. Synovial inflammation in osteoarthritis progression. Nature Reviews Rheumatology vol. 18 Preprint at https://doi.org/10.1038/s41584-022-00749-9 (2022). [2]Krenn, V. et al. Synovitis score: Discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, (2006). [3]KELLGREN, J. H. & LAWRENCE, J. S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16, (1957). Acknowledgements: NIL. Disclosure of Interests None Declared.

  • Open Access

    POS1045 HISTOLOGICAL COMPOSITION OF (TENO)SYNOVIAL AND SYNOVIAL INFLAMMATION IN RHEUMATOID ARTHRITIS ACROSS DISEASE PHASES

    by L. A. Coletto, C. Tur, P. Rubortone, L. Verardi, C. DI Mario, B. Tolusso, L. Petricca, M. R. Gigante, M. Gessi, M. A. D’agostino, et al.

    Background Subclinical tenosynovitis arose as a primary sign of inflammation already in the pre-clinical phases of Rheumatoid Arthritis (RA) and tenosynovitis is a common feature of active state and might persist although sustained remission is achieved. Objectives To assess the histological features of (teno)synovium from the extensor digitorum tendons of the hand across RA trajectory and to compare it with paired synovial tissue samples. Methods Thirty-seven patients underwent minimally invasive ultrasound (US)-guided biopsy of the tenosynovium of extensor digitorum tendons [n=16 with clinically suspected arthralgia (CSA), n=19 with RA (n=4 naïve, n=6 resistant to csDMARDS, n=8 to bDMARDs, and n=1 in sustained remission respectively)]. Twenty-three out of 37 patients presenting CSA or clinically evident synovitis in a peripheral joint (whether anatomically adjacent or not to the tendon of interest) underwent US-guided synovial tissue (ST) biopsy also in that location. The Krenn synovitis score (KSS) and the inflammatory infiltrate using CD68/CD21/CD3/CD20 immunohistochemical (IHC) analysis were assessed for each sample. Results Tenosynovium belonging to the extensor digitorum compartment of the wrist was successfully collected using a minimally invasive US-guided technique that enabled to retrieve representative samples in terms of lining and sublining layers presence in 86.5% and 100% of cases, respectively. Considering the pre-arthritis subgroup, KSS was similar in ACPA/RFpos vs ACPA/RFneg CSA (p=0.5814) and KSS was contingent with RA activity, being significantly higher in naïve or resistant RA (ANOVA p0.999) and IHC showed comparable enrichment in terms of lining and sublining CD68pos, sublining CD20pos and CD3pos cells (for all comparisons p>0.05) between the two sites, in naive and c- or b-DMARDs resistant RA patients. The procedure was well tolerated, and no tendon injury occurred within 10 months follow-up. One patient developed local hematoma that recovered after topic treatment. Conclusion (Teno)synovium is a retrievable tissue through a minimally invasive procedure across RA trajectory and its inflammation is directly related to the disease state. Semiquantitative analysis showed comparable inflammatory degree and inflammatory cellular composition in adjacent anatomical sites of the same person. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.

  • Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry

    by Marco Sebastiani, Vincenzo Venerito, Serena Bugatti, Chiara Bazzani, Martina Biggioggero, Luca Petricca, Rosario Foti, Alessandra Bortoluzzi, Silvia Balduzzi, Elisa Visalli, et al.

    Objectives EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug (bDMARD) should be preferred after failure of a first bDMARD in the treatment of rheumatoid arthritis (RA). In particular, few data are available regarding the effectiveness of a second-line bDMARD after failure of abatacept (ABA), tocilizumab (TCZ), and rituximab (RTX). The aim of this study was to analyze the retention rate of a second line with tumor necrosis factor inhibitors (TNFi) or other mechanisms of action (MoAs), after the failure of either RTX, TCZ, or ABA. Methods Two hundred and seventy-eight RA patients from the Italian GISEA registry were included in the study. RTX was the first bDMARD in 18% of patients, ABA in 45.7%, and TCZ in 36.3%, while the second bDMARD was a TNFi (group 1) in 129 patients and an agent with a different MoA (group 2) in 149. Results During a median follow-up of 22 months (IQR 68), 129 patients discontinued their treatment; patients of group 1 discontinued the treatment more frequently than patients of group 2 (pp• A large proportion of rheumatoid arthritis patients fail the first biologic DMARD. • Few data are available about the efficacy of biologic DMARD after the failure of a non-TNF inhibitor. • Abatacept, rituximab, or tocilizumab seem to maintain a good retention rate after the failure of a first-course therapy with a non-TNF inhibitor.


  • Open Access

    Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry

    by Rosario Foti, Giovanni Lapadula, Gianfranco Ferraccioli, Luca Petricca, Giuseppe Lopalco, Giulia Cassone, Alberto Cauli, Roberto Caporali, Chiara Giannitti, Marco Sebastiani, et al.

    Objectives: This study aims to investigate the factors associated with early discontinuation (within one year) of etanercept (ETA) in rheumatoid arthritis (RA) patients who began ETA as first biologic disease-modifying antirheumatic drug (bDMARD) and who were entered into the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis; GISEA) registry. Patients and methods: This registry-based cohort study included 477 RA patients (95 males, 382 females; median age 53 years; range 18 to 83 years) who began ETA as first bDMARD. Patient demographics, disease features and drugs were re-evaluated after 12 months. Baseline predictors of ETA discontinuation were estimated by univariate and multivariate analyses using Cox regression model. Results: Seventy patients (14.7%) discontinued ETA during the first year (for inefficacy in 55.8%, adverse events in 28.6%, and other reasons in 6.5%). Concurrent conventional synthetic DMARDs (csDMARDs) were reported in 54.3% of patients, mainly methotrexate (MTX), while 52.4% of subjects took low doses of glucocorticoids. Patients stopping ETA more frequently showed one or more comorbidities, mainly cardiovascular diseases (28.6% vs. 15.7% in patients stopping and continuing ETA, respectively, p=0.009). The presence of comorbidities and a combination therapy with csDMARDs other than MTX were independent factors associated with early discontinuation of ETA at multivariate Cox analysis. Conclusion: Although ETA demonstrated a high persistence in biologic-naïve RA patients, about 15% of patients discontinued the treatment within 12 months. The presence of comorbidities and a combination therapy with csDMARDs other than MTX were the main factors for an early withdrawal of the drug.


  • Open Access

    SAT0027 DEVELOPMENT AND VALIDATION OF A NOMOGRAM COMBINING CLINICAL AND HISTOPATHOLOGICAL SYNOVIAL FEATURES FOR PREDICTING EARLY TREATMENT RESPONSE IN NAIVE TO TREATMENT RHEUMATOID ARTHRITIS

    by S. Alivernini, B. Tolusso, M. Gessi, M. R. Gigante, A. Mannocci, L. Petricca, S. Perniola, C. DI Mario, A. L. Fedele, L. Bui, et al.

    Background: Rheumatoid Arthritis (RA) is characterized by synovial tissue (ST) heterogeneity at disease onset in terms of inflammatory degree and microanatomical organization being related to treatment response. Objectives: To develop a multiparametric tool for baseline treatment response prediction including disease characteristics and histopathologic features of ST biopsies, using a large single center (SYNGem Unit) naive to treatment RA cohort. Methods: 240 naive to treatment RA who underwent US-guided ST biopsy, at the first clinical evaluation, were enrolled. Clinical and immunological characteristics were recorded for each patient. All ST FFPE specimens were stained with H&E and classified by a pathologist, blinded to clinical characteristics, using the Krenn score [1] to assess the degree of ST inflammation. All naive to treatment RA were treated according to the T2T scheme and DAS remission rate at 6-12 months was recorded. On the basis of the regression analysis, a nomogram was constructed that incorporated the significant factors predicting the “achievement of DAS-Remission at 6 months follow-up” in naive RA. The performance of the nomogram was assessed by discrimination and calibration. Results: Univariate analysis showed that RA who achieved early (6 months) DAS-remission had, at baseline, significantly lower total Krenn score (pConclusion: Krenn score is a reliable tool for the semi-quantitative assessment of ST inflammation on US-guided ST biopsies being contingent to baseline disease characteristics and can be integrated within a nomogram to better predict the therapeutic response in naive to treatment RA. References: [1] Krenn V, et al. Histopathology 2006 Disclosure of Interests: Stefano Alivernini: None declared, Barbara Tolusso: None declared, Marco Gessi: None declared, Maria Rita Gigante: None declared, Alice Mannocci: None declared, Luca Petricca: None declared, Simone Perniola: None declared, Clara Di Mario: None declared, Anna Laura Fedele: None declared, Laura Bui: None declared, Annunziata Capacci: None declared, Dario Bruno: None declared, Giuseppe La Torre: None declared, Francesco Federico: None declared, Gianfranco Ferraccioli: None declared, Elisa Gremese Speakers bureau: Abbvie, BMS, Celgene, Jannsen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB

  • Open Access

    SAT0224 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS

    by A. Paglionico, V. Varriano, L. Petricca, G. Vischini, C. DI Mario, M. R. Gigante, G. Tanti, S. Costanzi, G. Grandaliano, B. Tolusso, et al.

    Background: Several studies have showed that antiphospholipid antibodies (aPL) positivity represents a predictor of worse renal outcome in patients with Lupus Nephritis (LN). In addition, an association between aPL positivity and the histological data of vascular lesions on the renal biopsies has been reported. Objectives: To determine the prognostic role of aPL and vascular renal lesions in the assessment of clinical outcome during the follow up period, in terms of time to achieve remission, number of renal flares and development of chronic renal damage in patients affected by LN. Methods: Among 120 patients affected by LN from our Rheumatology Unit, 91 patients (age 43.8 ± 12 years, 74 (81.3%) female, disease duration 7.1 ± 7.9 years) have been evaluated and the follow-up data have been collected at the baseline and at 6, 12, 24 months and at the last follow-up visit. Histopathological data of 41 patients were evaluated according to the 2016 revision of ISN/RPS classification. Results: Among the 91 LN patients, 31 (34.1%) were aPL positive (aPL+), 10 (32.2%) of them were affected by Antiphospholipid Antibodies Syndrome (APS), 53.3% showed a single aPL positivity, 23.1% double aPL positivity and 15.4% triple aPL positivity. At the last follow up visit a significant higher number of aPL+ patients showed a persistent complement consumption than aPL negative (aPL-) patients (p=0.001). Evaluating clinical outcome, we observed that aPL- patients showed a remission achievement time slightly earlier than aPL+ patients (13.6 ± 1.0 months vs 16.5 ± 1.5 months; log-rank test: p=0.06, Breslow test: p=0.08) and as expected, patients with a persistent complement consumption achieve remission later (18.2 ± 1.5 months vs 13.0 ± 1 months; log-rank test: p=0.002, Breslow test: p=0.003). Furthermore at the last follow up, a significant higher percentage of aPL+ patients developed persistent proteinuria (p=0.02) and chronic renal failure (p=0.04). Considering histologic features (activity and chronicity index, glomerulonephritis class, presence of mesangiolysis, glomerular wrinkling, glomerular thrombi, interstitial inflammatory infiltrates, interstitial fibrosis and tubular atrophy,tubulitis and vascular lesions) we didn’t observe significant differences between aPL+ and aPL- patients but we found two typical vascular lesions (mesangiolysis and vascular thrombi) only in aPL + patients. Conclusion: aPL positivity is a predictor of worse renal outcome but in our cohort of LN patients we didn’t find an association between aPL positivity and vascular renal lesions at renal biopsy. The worse renal outcome and the late time to achieve remission in aPL+ group can be related to a cumulative vascular damage over time as observed in other organ and systems. Disclosure of Interests: None declared

  • Open Access

    P192 Evaluation of predictive factors of worse prognosis in lupus nephritis: focus on new pathogenetic pathways

    by Valentina Varriano, Annamaria Paglionico, Luca Petricca, Clara Di Mario, Maria Rita Gigante, Giacomo Tanti, Barbara Tolusso, Elisa Gremese

    Purpose To evaluate the prognostic factors in a cohort of patients with lupus nephritis (LN) focusing on of the IL-17, 23 axis as new pathogenetic pathway. Patients and Methods 91 LN patients were enrolled. Laboratory, immunological and disease activity data were collected at the baseline and at 6(T6),12(T12),24(T24) months and at the last follow-up(FU).84 renal biopsies were evaluated according to ISN/RPS classification, assessing the inflammatory interstitial infiltrate using the BANFF score. Baseline serum levels of IL-17 and IL-23 were assessed by ELISA in 37 patients. Results Among the 84 renal biopsies evaluated 77% belonged to class III and IV; 41,8% of patients had an interstitial infiltrate5% at renal biopsy and persistent proteinuria. Finally, we conducted an univariate and multivariate analysis for each renal outcome considered. We found that an inflammatory interstitial infiltrate>5% and APL+ were associated with worse renal outcome in terms of early and persistent remission, chronic damage, persistent proteinuria, and renal flare both in univariate and multivariate analysis. Higher serum level of IL-23 was associated with persistent proteinuria, renal flare and tended to be associated to chronic renal damage. Conclusion Interstitial infiltrate and APL+ resulted as the strongest predictors of worse renal outcome. An higher serum level of IL-23 resulted as a negative prognostic factor highlighting its possible role as a biomarkers of more aggressive disease.